Aurora expands into Portugal, agrees to acquire 51% stake in Gaia Pharm Lda

Aurora Cannabis has agreed to terms to acquire a 51% ownership interest in Gaia Pharm Lda., a license applicant in Portugal, to establish a local facility to produce medical cannabis and derivative products.

The company will be renamed Aurora Portugal Lda.

On February 21, 2019, Gaia Pharm Lda. received approval of its application to construct an EU GMP compliant cannabis cultivation facility from INFARMED, a division of the Portuguese Health Ministry, which is responsible for the evaluation, authorization, regulation and control of human medicines as well as health products for the protection of public health.

Construction of the new facility will be conducted in phases, with the first phase expected to be completed in the third calendar quarter of 2020.

Upon completion, the first phase of the facility is expected to have a production capacity of approximately 2,000 kg per annum, growing to 4,000 kg per annum upon completion of the second phase.

New Portuguese regulations enacted on January 15, 2019 permit the distribution of prescribed medical cannabis to Portuguese patients in addition to export to other European Union member countries where medical cannabis is currently legal.

“With the addition of this new project, we are now active in 24 countries, which we believe represents the largest global footprint of any cannabis company.”

Terry Booth, Aurora

Terry Booth, CEO of Aurora said: “We are very pleased to be entering yet another European market, and look forward to collaborating with our joint venture partners, the government of Portugal and the Portuguese medical community, to encourage the development of a rigorously regulated and safe medical cannabis system that is well supplied and accessible to patients.

“With the addition of this new project, we are now active in 24 countries, which we believe represents the largest global footprint of any cannabis company.

“Aurora’s reputation in the medical cannabis sector, bolstered by the high quality of our products and our commitment to medical and plant research, provides distinct advantages in establishing significant market share in the rapidly growing European market.”

“The formation of this joint venture and the approval of the cultivation facility in Portugal are additional important steps in Aurora’s plan to develop a strong European manufacturing presence.”

Dr. Axel Gille, Aurora’s VP Business Development Europe

Dr. Axel Gille, Aurora’s VP Business Development Europe, added: “The formation of this joint venture and the approval of the cultivation facility in Portugal are additional important steps in Aurora’s plan to develop a strong European manufacturing presence, ensuring that patients across Europe have access to the pharmaceutical grade medical cannabis they need.”Cannabis Business Worldwide